Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.37 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2422782 | 0.87 | CA12 (0.41) | CA12CA1CA9CA2ZDHHC20 | |
| SCHEMBL28762352 | 0.83 | CA1 (0.38) | CA12CA1CA9CA2ZDHHC20 | |
| SCHEMBL8924940 | 0.81 | PDE4A (0.43) | CA12CA1CA9CA2ZDHHC20 | |
| SCHEMBL20472611 | 0.81 | CA12 (0.45) | CA12CA1CA9CA2ZDHHC20 | |
| SCHEMBL8622413 | 0.81 | CA12 (0.45) | CA12CA1CA9CA2ZDHHC20 | |
| SCHEMBL8618803 | 0.81 | CA12 (0.45) | CA12CA1CA9CA2ZDHHC20 | |
| SCHEMBL2423529 | 0.80 | ZDHHC20 (0.37) | CA12CA1CA9CA2ZDHHC20 | |
| SCHEMBL15216631 | 0.79 | ZDHHC20 (0.46) | CA12CA1CA9CA2ZDHHC20 | |
| SCHEMBL4152729 | 0.79 | CA12 (0.47) | CA12CA1CA9CA2ZDHHC20 | |
| SCHEMBL22907546 | 0.79 | CA12 (0.47) | CA12CA1CA9CA2ZDHHC20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9320798-B2 | Lipid delivery formulations | DICERNA PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20130225663-A1 | LIPID DELIVERY FORMULATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225663-A1 | LIPID DELIVERY FORMULATIONS | LIPA, LIPC, CETP | CA12 4291/4885CA1 4588/4885CA9 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.